Please enable JavaScript to continue using this application.

Compare $CRDF vs $PTHS | Chartloom

Compare

$CRDF vs $PTHS

Cardiff Oncology Inc · Pelthos Therapeutics Inc

CRDF

Cardiff Oncology Inc

PTHS

Pelthos Therapeutics Inc

Compare $CRDF vs $PTHS

Comparing Cardiff Oncology Inc and Pelthos Therapeutics Inc

CRDFCardiff Oncology Inc

PTHSPelthos Therapeutics Inc

CRDFCardiff Oncology Inc

Market cap

$84M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

244.08x

Rev growth (TTM)

-7.0%

YTD performance

-59.4%

52W performance

-54.6%

FCF yield

-48.7%

PTHSPelthos Therapeutics Inc

Market cap

$71M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.83x

Rev growth (TTM)

—

YTD performance

-30.4%

52W performance

-27.4%

FCF yield

-70.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRDF

PTHS

Detailed metrics comparison

CRDF

Cardiff Oncology Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

CRDF$84M

PTHS$71M

Enterprise Value

CRDF$75M

PTHS$71M

Price

CRDF$1.08

PTHS$20.50

P/E Ratio

CRDFN/A

PTHSN/A

P/S Ratio

CRDF165.40x

PTHS1.65x

EV/Sales

CRDF147.30x

PTHS1.65x

EV/EBITDA

CRDF0.00x

PTHS0.00x

P/B Ratio

CRDF3.28x

PTHS2.03x

P/FCF Ratio

CRDFN/A

PTHSN/A

EV/FCF

CRDF-1.83x

PTHS-1.41x

PEG Ratio

CRDFN/A

PTHSN/A

Forward P/E (NTM)

CRDFN/A

PTHSN/A

Forward P/S (NTM)

CRDF244.08x

PTHS0.83x

Revenue (TTM)

CRDF$508K

PTHS$43M

Revenue Growth (YoY)

CRDF-7.0%

PTHSN/A

Forward Rev Growth

CRDF-19.6%

PTHS76.2%

Gross Margin (TTM)

CRDF100.0%

PTHS78.6%

Operating Margin (TTM)

CRDF0.0%

PTHS0.0%

EBITDA Margin (TTM)

CRDF-8251.0%

PTHS-121.6%

Net Margin (TTM)

CRDF-7889.0%

PTHS-165.2%

FCF Margin (TTM)

CRDF-8054.3%

PTHS-116.6%

Net Income (TTM)

CRDF$-40M

PTHS$-72M

FCF (TTM)

CRDF$-41M

PTHS$-50M

EPS (TTM)

CRDF-$0.59

PTHS-$20.22

ROE (TTM)

CRDF-10308.0%

PTHS-7804.0%

ROA (TTM)

CRDF-7551.0%

PTHS-6701.0%

ROIC (TTM)

CRDF-10308.0%

PTHS-5896.0%

Cash

CRDF$9M

PTHS$0

Debt

CRDF$0

PTHS$0

Net Cash/Debt

CRDF$9M

PTHS$0

Current Ratio (TTM)

CRDF3.30x

PTHS2.05x

Quick Ratio (TTM)

CRDF3.21x

PTHS1.10x

Debt/Equity (TTM)

CRDF0.00x

PTHS0.81x

Debt/Assets (TTM)

CRDF0.0%

PTHS0.0%

Interest Coverage (TTM)

CRDFN/A

PTHSN/A

Net Debt/EBITDA (TTM)

CRDF0.00x

PTHS0.00x

Beta

CRDF1.49

PTHS3.13

52W Performance

CRDF-54.6%

PTHS-27.4%

YTD Performance

CRDF-59.4%

PTHS-30.4%

% from 52W High

CRDF-67.4%

PTHS-45.3%

% from 52W Low

CRDF42.7%

PTHS12.7%

Asset Turnover (TTM)

CRDF0.01x

PTHS0.00x

FCF Yield (TTM)

CRDF-48.7%

PTHS-70.8%

Earnings Yield (TTM)

CRDF-47.7%

PTHS-100.3%

Dividend Yield (TTM)

CRDFN/A

PTHSN/A

Rule of 40

CRDF-8,061.3

PTHS-116.6

EV/GP/RG

CRDFN/A

PTHS0.02

Ticker research

View CRDF research View PTHS research

Metric	CRDF Cardiff Oncology Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$84M	$71M
Enterprise Value	$75M	$71M
Price	$1.08	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	165.40x	1.65x
EV/Sales	147.30x	1.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.28x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.83x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	244.08x	0.83x
Revenue & Growth
Revenue (TTM)	$508K	$43M
Revenue Growth (YoY)	-7.0%	N/A
Forward Rev Growth	-19.6%	76.2%
Profitability
Gross Margin (TTM)	100.0%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8251.0%	-121.6%
Net Margin (TTM)	-7889.0%	-165.2%
FCF Margin (TTM)	-8054.3%	-116.6%
Net Income (TTM)	$-40M	$-72M
FCF (TTM)	$-41M	$-50M
EPS (TTM)	-$0.59	-$20.22
ROE (TTM)	-10308.0%	-7804.0%
ROA (TTM)	-7551.0%	-6701.0%
ROIC (TTM)	-10308.0%	-5896.0%
Financial Health
Cash	$9M	$0
Debt	$0	$0
Net Cash/Debt	$9M	$0
Current Ratio (TTM)	3.30x	2.05x
Quick Ratio (TTM)	3.21x	1.10x
Debt/Equity (TTM)	0.00x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.49	3.13
52W Performance	-54.6%	-27.4%
YTD Performance	-59.4%	-30.4%
% from 52W High	-67.4%	-45.3%
% from 52W Low	42.7%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-48.7%	-70.8%
Earnings Yield (TTM)	-47.7%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,061.3	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View CRDF research	View PTHS research

Valuation

P/S Ratio

PTHS

1.65x

CRDF

165.40x

EV/FCF

CRDF

-1.83x

PTHS

-1.41x

Growth & revenue

Revenue Growth TTM

CRDF

-7.0%

Forward Revenue Growth

PTHS

76.2%

CRDF

-19.6%

Profitability & performance

Gross Margin

CRDF

100.0%

PTHS

78.6%

ROE

PTHS

-7804.0%

CRDF

-10308.0%

FCF Yield %

CRDF

-48.7%

PTHS

-70.8%

52-Week Performance

PTHS

-27.4%

CRDF

-54.6%

Detailed metrics comparison

CRDF

Cardiff Oncology Inc

PTHS

Pelthos Therapeutics Inc

Market Cap

CRDF$84M

PTHS$71M

Enterprise Value

CRDF$75M

PTHS$71M

Price

CRDF$1.08

PTHS$20.50

P/E Ratio

CRDFN/A

PTHSN/A

P/S Ratio

CRDF165.40x

PTHS1.65x

EV/Sales

CRDF147.30x

PTHS1.65x

EV/EBITDA

CRDF0.00x

PTHS0.00x

P/B Ratio

CRDF3.28x

PTHS2.03x

P/FCF Ratio

CRDFN/A

PTHSN/A

EV/FCF

CRDF-1.83x

PTHS-1.41x

PEG Ratio

CRDFN/A

PTHSN/A

Forward P/E (NTM)

CRDFN/A

PTHSN/A

Forward P/S (NTM)

CRDF244.08x

PTHS0.83x

Revenue (TTM)

CRDF$508K

PTHS$43M

Revenue Growth (YoY)

CRDF-7.0%

PTHSN/A

Forward Rev Growth

CRDF-19.6%

PTHS76.2%

Gross Margin (TTM)

CRDF100.0%

PTHS78.6%

Operating Margin (TTM)

CRDF0.0%

PTHS0.0%

EBITDA Margin (TTM)

CRDF-8251.0%

PTHS-121.6%

Net Margin (TTM)

CRDF-7889.0%

PTHS-165.2%

FCF Margin (TTM)

CRDF-8054.3%

PTHS-116.6%

Net Income (TTM)

CRDF$-40M

PTHS$-72M

FCF (TTM)

CRDF$-41M

PTHS$-50M

EPS (TTM)

CRDF-$0.59

PTHS-$20.22

ROE (TTM)

CRDF-10308.0%

PTHS-7804.0%

ROA (TTM)

CRDF-7551.0%

PTHS-6701.0%

ROIC (TTM)

CRDF-10308.0%

PTHS-5896.0%

Cash

CRDF$9M

PTHS$0

Debt

CRDF$0

PTHS$0

Net Cash/Debt

CRDF$9M

PTHS$0

Current Ratio (TTM)

CRDF3.30x

PTHS2.05x

Quick Ratio (TTM)

CRDF3.21x

PTHS1.10x

Debt/Equity (TTM)

CRDF0.00x

PTHS0.81x

Debt/Assets (TTM)

CRDF0.0%

PTHS0.0%

Interest Coverage (TTM)

CRDFN/A

PTHSN/A

Net Debt/EBITDA (TTM)

CRDF0.00x

PTHS0.00x

Beta

CRDF1.49

PTHS3.13

52W Performance

CRDF-54.6%

PTHS-27.4%

YTD Performance

CRDF-59.4%

PTHS-30.4%

% from 52W High

CRDF-67.4%

PTHS-45.3%

% from 52W Low

CRDF42.7%

PTHS12.7%

Asset Turnover (TTM)

CRDF0.01x

PTHS0.00x

FCF Yield (TTM)

CRDF-48.7%

PTHS-70.8%

Earnings Yield (TTM)

CRDF-47.7%

PTHS-100.3%

Dividend Yield (TTM)

CRDFN/A

PTHSN/A

Rule of 40

CRDF-8,061.3

PTHS-116.6

EV/GP/RG

CRDFN/A

PTHS0.02

Ticker research

View CRDF research View PTHS research

Metric	CRDF Cardiff Oncology Inc	PTHS Pelthos Therapeutics Inc
Market & Valuation
Market Cap	$84M	$71M
Enterprise Value	$75M	$71M
Price	$1.08	$20.50
P/E Ratio	N/A	N/A
P/S Ratio	165.40x	1.65x
EV/Sales	147.30x	1.65x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.28x	2.03x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.83x	-1.41x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	244.08x	0.83x
Revenue & Growth
Revenue (TTM)	$508K	$43M
Revenue Growth (YoY)	-7.0%	N/A
Forward Rev Growth	-19.6%	76.2%
Profitability
Gross Margin (TTM)	100.0%	78.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-8251.0%	-121.6%
Net Margin (TTM)	-7889.0%	-165.2%
FCF Margin (TTM)	-8054.3%	-116.6%
Net Income (TTM)	$-40M	$-72M
FCF (TTM)	$-41M	$-50M
EPS (TTM)	-$0.59	-$20.22
ROE (TTM)	-10308.0%	-7804.0%
ROA (TTM)	-7551.0%	-6701.0%
ROIC (TTM)	-10308.0%	-5896.0%
Financial Health
Cash	$9M	$0
Debt	$0	$0
Net Cash/Debt	$9M	$0
Current Ratio (TTM)	3.30x	2.05x
Quick Ratio (TTM)	3.21x	1.10x
Debt/Equity (TTM)	0.00x	0.81x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.49	3.13
52W Performance	-54.6%	-27.4%
YTD Performance	-59.4%	-30.4%
% from 52W High	-67.4%	-45.3%
% from 52W Low	42.7%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-48.7%	-70.8%
Earnings Yield (TTM)	-47.7%	-100.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-8,061.3	-116.6
EV/GP/RG	N/A	0.02
Ticker research	View CRDF research	View PTHS research